Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

333
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
333
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

294
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
294
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

401
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
401
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

615
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
615
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

259
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
259
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
189

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of Self-Reported Non-Coeliac Gluten Sensitivity and Its Association With Disorders of Gut-Brain Interaction and Disordered Eating.

United European gastroenterology journal·2026
Same author

The Rome V criteria for the diagnosis of irritable bowel syndrome in secondary care: a diagnostic accuracy study.

The lancet. Gastroenterology & hepatology·2026
Same author

Expert Clinical Consensus on Body Surface Gastric Mapping Phenotypes for Gastroduodenal Disorders: 'Auckland Classification' v1.0.

Neurogastroenterology and motility·2026
Same author

Effect of icosapent ethyl treatment on colorectal tissue marine omega-3 polyunsaturated fatty acid levels among patients with a history of adenoma: a prospective, single-arm clinical trial.

The American journal of clinical nutrition·2026
Same author

From Adaptive to Maladaptive Eating Behavior in Disorders of Gut-Brain Interaction.

Neurogastroenterology and motility·2026
Same author

Irritable Bowel Syndrome with Constipation: Diagnosis and Multisymptom Management Beyond Abdominal Pain and Bowel Movement Frequency: A Review.

Advances in therapy·2026
Same journal

M2 macrophage activation in recurrent acute pancreatitis: an explorative analysis of a randomized controlled trial.

Scandinavian journal of gastroenterology·2026
Same journal

Safety and performance of small bowel capsule endoscopy in patients with surgically altered gastrointestinal anatomy.

Scandinavian journal of gastroenterology·2026
Same journal

Textbook outcome after esophagectomy in Norway - a national cohort study of low- to medium-volume centers.

Scandinavian journal of gastroenterology·2026
Same journal

Fecal calprotectin concentration in adults with and without <i>Helicobacter pylori</i> infection.

Scandinavian journal of gastroenterology·2026
Same journal

Endoloop-clip closure versus hemoclips for large sigmoid colon perforations: a randomized controlled <i>ex vivo</i> study.

Scandinavian journal of gastroenterology·2026
Same journal

Outcomes associated with secondary spontaneous bacterial peritonitis (SBP) prophylaxis after hospital discharge in a nation-wide Swedish cohort.

Scandinavian journal of gastroenterology·2026
See all related articles

Related Experiment Video

Updated: Sep 12, 2025

Autonomous and Rechargeable Microneurostimulator Endoscopically Implantable into the Submucosa
08:17

Autonomous and Rechargeable Microneurostimulator Endoscopically Implantable into the Submucosa

Published on: September 27, 2018

8.6K

Pharmacologic neuromodulation for bloating.

Elizabeth N Madva1,2,3, Sanskriti Varma1,2, Victoria Small2

  • 1Harvard Medical School, Boston, MA, USA.

Scandinavian Journal of Gastroenterology
|August 8, 2025
PubMed
Summary
This summary is machine-generated.

Pharmacologic neuromodulators show promise for treating bloating in patients with disorders of gut-brain interaction (DGBI). Younger age was linked to better treatment response, suggesting targeted use for this common symptom.

Keywords:
Brain-Gut axisconstipationfunctional dyspepsiafunctional gastrointestinal disordersirritable bowel syndromepharmacology

More Related Videos

Fabrication and Implantation of Miniature Dual-element Strain Gages for Measuring In Vivo Gastrointestinal Contractions in Rodents.
09:29

Fabrication and Implantation of Miniature Dual-element Strain Gages for Measuring In Vivo Gastrointestinal Contractions in Rodents.

Published on: September 18, 2014

10.4K
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

342

Related Experiment Videos

Last Updated: Sep 12, 2025

Autonomous and Rechargeable Microneurostimulator Endoscopically Implantable into the Submucosa
08:17

Autonomous and Rechargeable Microneurostimulator Endoscopically Implantable into the Submucosa

Published on: September 27, 2018

8.6K
Fabrication and Implantation of Miniature Dual-element Strain Gages for Measuring In Vivo Gastrointestinal Contractions in Rodents.
09:29

Fabrication and Implantation of Miniature Dual-element Strain Gages for Measuring In Vivo Gastrointestinal Contractions in Rodents.

Published on: September 18, 2014

10.4K
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

342

Area of Science:

  • Neurogastroenterology
  • Pharmacology
  • Gastroenterology

Background:

  • Bloating is a common and distressing symptom in disorders of gut-brain interaction (DGBI).
  • Limited targeted treatment options currently exist for DGBI-related bloating.
  • This study investigates neuromodulators as a specific treatment for bloating.

Purpose of the Study:

  • To examine the efficacy of pharmacologic neuromodulators in treating bloating.
  • To identify factors associated with treatment response in DGBI patients.

Main Methods:

  • Retrospective study of 77 DGBI patients (ages 18-74) treated between 2016-2022.
  • Assessed patient-reported bloating response (0-100%) to maximum neuromodulator dose.
  • Used multivariable logistic regression, adjusting for covariates.

Main Results:

  • 61% of patients reported any symptom improvement (>0%).
  • 36.4% met the responder definition (≥50% improvement).
  • Younger age was the only significant factor associated with increased odds of response (OR 1.04).

Conclusions:

  • Pharmacologic neuromodulators show potential for managing DGBI-related bloating.
  • Further research is needed to optimize their use.
  • Younger patients may benefit more from these treatments.